Osteogenesis imperfecta (OI) is a genetic disorder that makes bones extremely fragile and prone to fracturing, sometimes with little or no force. Often called “brittle bone disease,” it affects roughly 1 in every 16,000 to 20,000 births. The condition ranges widely in severity, from people who experience only a handful of fractures in a lifetime to infants whose bones break before or during birth.
What Causes Brittle Bones in OI
The root problem in most cases of OI is a defect in type I collagen, a protein that acts as the structural scaffolding of bone, skin, tendons, and the whites of your eyes. Collagen is built from three protein chains twisted together like a rope. Two of these chains come from the COL1A1 gene and one from the COL1A2 gene. A mutation in either gene disrupts the final product.
How the mutation disrupts collagen determines how severe the disease is. In milder forms, the body simply produces less collagen than it should, but the collagen it does make is structurally normal. There’s not enough raw material to build strong bones, so they break more easily than they should, but the basic architecture holds up reasonably well.
In more severe forms, the mutation changes the shape of the collagen molecule itself. One critical pattern involves glycine, the smallest amino acid, which must sit in every third position along the chain to allow proper folding. When a different, larger amino acid takes glycine’s place, the chain can’t fold correctly. The misshapen collagen gets incorporated into bone and other tissues, weakening them from the inside out. This is why structural mutations cause far more damage than simply having less collagen: the abnormal protein actively undermines every tissue it becomes part of.
Types and Severity
OI is classified into several types, originally organized by a system developed by David Sillence in the late 1970s. The four main types capture the range from barely noticeable to fatal.
Type I is the mildest and most common form, making up roughly half of all cases. Fractures typically begin in early childhood, and most people with Type I develop normal motor skills and walk independently. About 30% have short stature. The whites of the eyes often have a noticeable blue tint. Importantly, studies show no significant excess mortality compared to the general population, meaning life expectancy is essentially normal.
Type II is the most severe form and is fatal either before or shortly after birth. Bones are so fragile that they fracture in the womb, and the skull is severely undermineralized. Ribs may appear “beaded” on X-rays due to multiple fractures along their length.
Type III is the most severe form compatible with survival. Fractures often begin at birth and continue throughout life. Over 90% of people with Type III have short stature, and about half experience significantly delayed motor development or are unable to move independently. Most require a wheelchair or walker, particularly for longer distances.
Type IV falls between Types I and III. Fractures frequently start in infancy, and about 75% of people with this type have short stature. Roughly half achieve normal motor development, though about a third experience arrested development. Around 24% need assistive devices like walkers, crutches, or canes.
Researchers have since identified additional types (V through IX and beyond), each linked to different genetic pathways. Type V, for instance, is recognized by unusual calcification in the forearm and formation of excessive callus tissue at fracture sites.
Symptoms Beyond Fragile Bones
Because type I collagen is found throughout the body, OI affects more than just the skeleton. The most recognizable sign, aside from fractures, is a blue or blue-gray tint to the sclera, the white part of the eye. This happens because the collagen layer in the sclera is thinner than normal, allowing the underlying tissue to show through. The tint is most obvious in natural or direct light and is especially common in Type I.
About 50% of people with OI develop a dental condition where the teeth appear translucent or opalescent and wear down more quickly than normal. The internal structure of the teeth, the dentin layer, forms abnormally, making teeth weaker and more prone to chipping and discoloration.
Hearing loss is another common feature, particularly in adults. It can result from abnormal bone formation in the tiny bones of the middle ear. The degree varies, but progressive hearing loss affects a significant proportion of people with OI as they age.
How OI Is Diagnosed
Severe forms of OI can be identified before birth through ultrasound, which may reveal shortened limbs, bowed bones, or fractures already present in the womb. Milder forms are often suspected after a child experiences fractures that seem disproportionate to the force involved, such as a broken bone from being picked up or rolling over in a crib.
Genetic testing is the most definitive diagnostic tool. Identifying a mutation in COL1A1 or COL1A2 confirms the diagnosis in the majority of cases. When genetic testing is inconclusive, doctors can grow skin cells in a lab and analyze the collagen they produce, checking whether the amount or structure is abnormal. This biochemical approach has caught cases that clinical evaluation alone missed. X-rays also play a supporting role, revealing patterns like low bone mineralization, compressed vertebrae, or bowed long bones that point toward OI rather than other causes of fractures.
One important context for diagnosis: distinguishing OI from child abuse is a genuine clinical challenge, since unexplained fractures in young children raise both possibilities. Thorough genetic and biochemical testing helps resolve this question definitively.
Medications That Strengthen Bone
Bisphosphonates are the cornerstone of drug treatment for OI. These medications slow down the cells that break down bone, allowing bone density to build up over time. Clinical trials have consistently shown that both oral and intravenous bisphosphonates improve bone mineral density in people with OI. The practical goals are straightforward: fewer fractures, less bone deformity, reduced pain, and better mobility.
Two intravenous bisphosphonates, pamidronate and zoledronic acid, have been compared directly, with no significant overall difference in outcomes. The choice between them often comes down to practical considerations like dosing schedule and how well each is tolerated.
A newer class of treatment targets a protein called sclerostin, which normally puts the brakes on bone formation. By blocking sclerostin with an antibody called setrusumab, researchers aim to actively stimulate new bone growth rather than just slowing bone loss. A phase 2b clinical trial showed that setrusumab improved estimates of bone strength across different OI types, and the drug is moving toward larger phase 3 trials.
Surgery for Bone Deformities
When long bones bow severely or fracture repeatedly, surgeons can straighten them and reinforce them from the inside with metal rods placed down the center of the bone. Traditional rods like Rush nails provided stability but had a significant drawback: children outgrow them, requiring repeated surgeries every few years.
Telescoping rods, such as the Fassier-Duval nail, solved this problem. These rods are designed in two interlocking pieces that slide apart as the bone grows, much like extending a telescope. The rod automatically lengthens with the child, maintaining support throughout skeletal development and dramatically reducing the number of surgeries needed. The procedure is performed through small incisions using real-time X-ray guidance, with targeted cuts to correct the deformity before the rod is inserted and locked into place.
Physical Activity and Mobility
The central goal of rehabilitation in OI is maintaining the highest level of physical activity possible without causing injury. This sounds like a tightrope walk, and it is. Too little activity leads to muscle weakness and further bone loss, since bones need mechanical loading to stay strong. Too much activity risks fractures. Finding the right balance is individualized and changes over time.
Mobility varies enormously by type. Nearly all people with Type I walk independently on all surfaces, and only about 4% use any assistive device. For Type III, the picture is very different: most people rely on a wheelchair or walker, especially for longer distances, with 40% requiring assistive devices. Type IV falls in between, with about 24% needing devices, most commonly a walker.
Rehabilitation for mild to moderate OI focuses on building enough strength and endurance to promote independence. For more severe forms, the focus shifts toward safe positioning, transfers, and maximizing whatever independent movement is possible. Swimming and water-based exercise are popular choices across severity levels because water supports body weight while still allowing muscles and bones to work.